{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:05:52Z","timestamp":1791223552273,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To describe the baseline characteristics of participants randomized in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE\u2010TIMI 58) trial, the pivotal study conducted to assess cardiovascular (CV) outcomes with dapagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The DECLARE\u2010TIMI 58 trial will analyse 17 160 patients with type 2 diabetes randomized to treatment with dapagliflozin (10 mg\/d) or matching placebo. We analysed their baseline characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The participants\u2019 mean \u00b1 SD age was 63.8 \u00b1 6.8 years, 62.6% were male, and their mean \u00b1 SD diabetes duration was 11.8 \u00b1 7.8 years, glycated haemoglobin 8.3% \u00b1 1.2% (67 mmol\/mol \u00b1 9.7 mmol\/mol) and body mass index 32.1 \u00b1 6.0 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Randomization included 6971 (40.6%) patients with atherosclerotic CV disease (CVD), and 10 189 (59.4%) patients with multiple risk factors (MRF) for CVD (defined as men age \u2265 55 years or women \u226560 years, with at least one of dyslipidaemia, hypertension or smoking). Patients with CVD compared with patients with MRF were younger (62.5 \u00b1 8.1 vs 64.7 \u00b1 5.6 years), more frequently male (72.1% vs 56.1%), less often used metformin (74.6% vs 81.2%), more often used insulin (44.2% vs 36.4%), and more frequently used statins, aspirin, clopidogrel and \u03b2\u2010blockers (82.2%, 71.1%, 24.7% and 66.6% vs 63.7%, 39.1%, 1.5% and 32.3%, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The DECLARE\u2010TIMI 58 trial is expected to provide conclusive data on the effect of treatment with dapagliflozin in addition to standard of care, on CV outcomes in a broad patient population with type 2 diabetes and CVD or MRF for CVD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13217","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T01:16:54Z","timestamp":1515633414000},"page":"1102-1110","source":"Crossref","is-referenced-by-count":102,"title":["<scp>DECLARE\u2010TIMI<\/scp>\n                    58: Participants\u2019 baseline characteristics"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0209-4453","authenticated-orcid":false,"given":"Itamar","family":"Raz","sequence":"first","affiliation":[{"name":"Diabetes Unit, Department of Internal Medicine Hadassah Hebrew University Hospital  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofri","family":"Mosenzon","sequence":"additional","affiliation":[{"name":"Diabetes Unit, Department of Internal Medicine Hadassah Hebrew University Hospital  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-9994","authenticated-orcid":false,"given":"Avivit","family":"Cahn","sequence":"additional","affiliation":[{"name":"Diabetes Unit, Department of Internal Medicine Hadassah Hebrew University Hospital  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri T.","family":"Kato","sequence":"additional","affiliation":[{"name":"Kyoto University Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Silverman","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1040-6229","authenticated-orcid":false,"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute St. Michael's Hospital, University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center  Dallas Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-8404","authenticated-orcid":false,"given":"John P. H.","family":"Wilding","sequence":"additional","affiliation":[{"name":"Obesity and Endocrinology Research Group University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A. M.","family":"Gause\u2010Nilsson","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Langkilde","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Johansson","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Wiviott","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0029"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30308-X"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00055.2009"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1863"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0612"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02911.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0779"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0517"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"issue":"1","key":"e_1_2_6_15_1","first-page":"A146","article-title":"Sustained efficacy of dapagliflozin when added to metformin in type 2 diabetes inadequately controlled by metformin monotherapy","volume":"54","author":"Baily CJ","year":"2011","journal-title":"Diabetologia"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12459"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00417-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/08037051.2015.1116258"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814544153"},{"key":"e_1_2_6_21_1","first-page":"1A","article-title":"Dapagliflozin reduces albuminuria over 2 years in diabetic patients with renal impairment [Abstract]","volume":"26","author":"Fioretto P","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12654"},{"key":"e_1_2_6_23_1","unstructured":"Electronic Medicines Compendium (eMC). Forxiga 5 mg & 10 mg film coated tablets.2013.https:\/\/www.medicines.org.uk\/emc\/medicine\/27188. Accessed February 4 2018."},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00204-1"},{"key":"e_1_2_6_26_1","unstructured":"U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana Invokamet) and dapagliflozin (Farxiga Xigduo XR).2016.https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm505860.htm. Accessed February 4 2018."},{"key":"e_1_2_6_27_1","unstructured":"Guidance for industry diabetes mellitus \u2014 Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [article online].2008.http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf. Accessed February 4 2018."},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0356-y"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00052-8"},{"key":"e_1_2_6_33_1","unstructured":"Am Heart J"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.07.017"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0542"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4157-3"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000496"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:40Z","timestamp":1761870340000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/dom.13217"],"URL":"https:\/\/doi.org\/10.1111\/dom.13217","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]}}}